<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6805592/results/search/disease/results.xml">
  <result pre="Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung" exact="Disease" post="Hannover (BREATH), Member of the German Center for Lung"/>
  <result pre="as rupintrivir may have an immune-modulatory effect in experimentally induced" exact="allergic asthma" post="with subsequent RV infection. We infected lung slices of"/>
  <result pre="rupintrivir may have an immune-modulatory effect in experimentally induced allergic" exact="asthma" post="with subsequent RV infection. We infected lung slices of"/>
  <result pre="TH-2/TH-17-dominated cytokine response that persisted in PCLS ex vivo. RV" exact="infection" post="of PCLS from non-sensitized mice resulted in the induction"/>
  <result pre="supplementary material, which is available to authorized users. Keywords Rhinovirus" exact="Infection" post="Asthma Exacerbation Lung sections Funding http://dx.doi.org/10.13039/501100010564Deutsche Zentrum für Lungenforschung"/>
  <result pre="material, which is available to authorized users. Keywords Rhinovirus Infection" exact="Asthma" post="Exacerbation Lung sections Funding http://dx.doi.org/10.13039/501100010564Deutsche Zentrum für Lungenforschung Background"/>
  <result pre="Exacerbation Lung sections Funding http://dx.doi.org/10.13039/501100010564Deutsche Zentrum für Lungenforschung Background Upper" exact="respiratory" post="tract infections, such as the common cold, are usually"/>
  <result pre="viruses and are self-limiting in healthy individuals. In patients with" exact="chronic" post="pulmonary diseases such as asthma and chronic obstructive pulmonary"/>
  <result pre="and are self-limiting in healthy individuals. In patients with chronic" exact="pulmonary" post="diseases such as asthma and chronic obstructive pulmonary disease"/>
  <result pre="healthy individuals. In patients with chronic pulmonary diseases such as" exact="asthma" post="and chronic obstructive pulmonary disease (COPD), human rhinovirus (RV)"/>
  <result pre="In patients with chronic pulmonary diseases such as asthma and" exact="chronic" post="obstructive pulmonary disease (COPD), human rhinovirus (RV) infections can"/>
  <result pre="with chronic pulmonary diseases such as asthma and chronic obstructive" exact="pulmonary disease" post="(COPD), human rhinovirus (RV) infections can be more severe"/>
  <result pre="chronic pulmonary diseases such as asthma and chronic obstructive pulmonary" exact="disease" post="(COPD), human rhinovirus (RV) infections can be more severe"/>
  <result pre="asthma and chronic obstructive pulmonary disease (COPD), human rhinovirus (RV)" exact="infections" post="can be more severe and associated with a decline"/>
  <result pre="dysregulated host antiviral immune responses in asthmatic patients, leading to" exact="viral" post="transmission from the upper to the lower respiratory tract."/>
  <result pre="responses in asthmatic patients, leading to viral transmission from the" exact="upper" post="to the lower respiratory tract. A disrupted epithelial barrier"/>
  <result pre="patients, leading to viral transmission from the upper to the" exact="lower" post="respiratory tract. A disrupted epithelial barrier and attenuated elimination"/>
  <result pre="leading to viral transmission from the upper to the lower" exact="respiratory" post="tract. A disrupted epithelial barrier and attenuated elimination of"/>
  <result pre="from the upper to the lower respiratory tract. A disrupted" exact="epithelial" post="barrier and attenuated elimination of viruses by ciliary dysfunction"/>
  <result pre="attenuated elimination of viruses by ciliary dysfunction results in stronger" exact="viral" post="propagation [1–4], which finally can lead to morbidity and"/>
  <result pre="synthetic 3C protease inhibitor, with potent in vitro activity against" exact="viral" post="serotypes [8]. The 3C protease is essential for cleaving"/>
  <result pre="precursor into structural proteins and enzymes that are required for" exact="viral" post="replication [9]. In in vitro cell cultures of BEAS-2B"/>
  <result pre="in vitro cell cultures of BEAS-2B (an immortalized human bronchial" exact="epithelial" post="cell line) rupintrivir has shown potent antiviral activity as"/>
  <result pre="rupintrivir failed to show beneficial effects in patients with naturally" exact="acquired" post="colds with no underlying chronic respiratory disease [11]. In"/>
  <result pre="effects in patients with naturally acquired colds with no underlying" exact="chronic" post="respiratory disease [11]. In this double-blinded clinical trial, rupintrivir"/>
  <result pre="in patients with naturally acquired colds with no underlying chronic" exact="respiratory" post="disease [11]. In this double-blinded clinical trial, rupintrivir was"/>
  <result pre="patients with naturally acquired colds with no underlying chronic respiratory" exact="disease" post="[11]. In this double-blinded clinical trial, rupintrivir was applied"/>
  <result pre="failed to relieve symptoms in healthy individuals, patients with prolonged" exact="chronic" post="lung diseases may benefit from a drug preventing symptom"/>
  <result pre="to relieve symptoms in healthy individuals, patients with prolonged chronic" exact="lung diseases" post="may benefit from a drug preventing symptom amplification. The"/>
  <result pre="a drug preventing symptom amplification. The effect of rupintrivir in" exact="allergic asthma" post="is unknown and has not been investigated so far."/>
  <result pre="drug preventing symptom amplification. The effect of rupintrivir in allergic" exact="asthma" post="is unknown and has not been investigated so far."/>
  <result pre="obtained from GREER (Lenoir, NC, USA). Animals and husbandry conditions" exact="Female" post="mice (Balb/c, 6–8 weeks) were obtained from Charles River (Sulzfeld,"/>
  <result pre="conventional housing conditions (22 °C, 55% humidity, and 12 h day/night rhythm). HDM-induced" exact="chronic" post="allergic airway inflammation Balb/c mice were sensitized by intranasal"/>
  <result pre="(320 g, 10 min, 4 °C) and the supernatant immediately frozen at − 80 °C." exact="Total" post="cell count of cells resuspended in 0.5 ml of PBS"/>
  <result pre="debris. Only PCLS containing an airway with an intact smooth" exact="muscle" post="layer and active beating of the cilia were selected"/>
  <result pre="The approach was repeated with 5 mice (n = 5) per group." exact="Viral" post="titer The viral titer (tissue culture infection dose 50,"/>
  <result pre="repeated with 5 mice (n = 5) per group. Viral titer The" exact="viral" post="titer (tissue culture infection dose 50, TCID50) of the"/>
  <result pre="(n = 5) per group. Viral titer The viral titer (tissue culture" exact="infection" post="dose 50, TCID50) of the Virapur RV1b stock was"/>
  <result pre="of the stock was 1.05 × 107 IU/mL (infectious units per mL). RV" exact="infection" post="of PCLS Two PCLS per well were infected with"/>
  <result pre="used under the same conditions. Pharmacological intervention was performed by" exact="infection" post="with RV (1 × 105 IU/mL) in the presence of 100 nM rupintrivir."/>
  <result pre="protease inhibitor cocktail and stored at − 80 °C for further analysis." exact="Protein" post="determination The total protein amount of the samples was"/>
  <result pre="and stored at − 80 °C for further analysis. Protein determination The" exact="total" post="protein amount of the samples was determined using the"/>
  <result pre="described previously [15]. Measurement of pro-inflammatory and antiviral cytokines (ELISA/MSD)" exact="Mouse" post="IFN-α, IFN-β, IL-6, MCP-1, and IP-10 were quantified using"/>
  <result pre="The cytokine content of each sample was related to the" exact="total" post="protein content (pg cytokine/mg total protein). Calcein AM/ethidium homodimer-1"/>
  <result pre="sample was related to the total protein content (pg cytokine/mg" exact="total" post="protein). Calcein AM/ethidium homodimer-1 (LIVE/DEAD®) staining and quantitative image"/>
  <result pre="ratio of counted dead cell nuclei (ethidium homodimer-1 positive) to" exact="total" post="volume of cytoplasm of living cells (calcein stained) was"/>
  <result pre="To gain first insight about the efficacy of rupintrivir in" exact="lower" post="respiratory tract infections under asthmatic conditions, the cytokine response"/>
  <result pre="gain first insight about the efficacy of rupintrivir in lower" exact="respiratory" post="tract infections under asthmatic conditions, the cytokine response to"/>
  <result pre="insight about the efficacy of rupintrivir in lower respiratory tract" exact="infections" post="under asthmatic conditions, the cytokine response to RV infection"/>
  <result pre="tract infections under asthmatic conditions, the cytokine response to RV" exact="infection" post="and the effect of rupintrivir on this response were"/>
  <result pre="non-sensitized mice. Viability of PCLS was not affected throughout the" exact="infection" post="experiment as confirmed by confocal imaging of calcein AM"/>
  <result pre="HDM-sensitized and non-sensitized mice were infected with RV for 48 h." exact="Infection" post="caused a slight accumulation of dead cells around airways"/>
  <result pre="airways although that increase was not sufficient to change the" exact="total" post="number of dead cells. The viral load in tissue"/>
  <result pre="sufficient to change the total number of dead cells. The" exact="viral" post="load in tissue culture supernatant was quantified 48 h p.i."/>
  <result pre="load in tissue culture supernatant was quantified 48 h p.i. as" exact="infectious" post="units (IU) assessed by dilution plating on HeLa cells"/>
  <result pre="dilution plating on HeLa cells and calculation of tissue culture" exact="infective" post="dose 50 (TCID50) based on observation of cytopathic effects."/>
  <result pre="of about 500 μm. Accordingly, only one circular layer of airway" exact="epithelial" post="cells lining this airway can be infected by RV."/>
  <result pre="this airway can be infected by RV. Consequently, as the" exact="total" post="number of airway epithelial cells in lung tissue sections"/>
  <result pre="infected by RV. Consequently, as the total number of airway" exact="epithelial" post="cells in lung tissue sections ex vivo is very"/>
  <result pre="(compared to conventional cell culture infections), and not all airway" exact="epithelial" post="cells get infected, the number of virions released from"/>
  <result pre="Thus, any additional increase of virus load based on active" exact="viral" post="replication in these few cells was not detectable by"/>
  <result pre="from non-sensitized mice showed a strong antiviral response to active" exact="viral infection," post="which resulted in enhanced secretion of IFN-α (0.4 vs."/>
  <result pre="under the experimental conditions in lung tissue of HDM-sensitized mice." exact="Reduced" post="levels of IFN-β (267 vs. 500 pg/mg), MCP-1 (28 vs."/>
  <result pre="with 125 pg/mg. Fig. 2 Antiviral cytokine response to RV (rhinovirus)" exact="infection" post="is impaired in PCLS of HDM-sensitized mice and shows"/>
  <result pre="infection is impaired in PCLS of HDM-sensitized mice and shows" exact="limited" post="response to rupintrivir treatment. PCLS from non-sensitized and HDM-sensitized"/>
  <result pre="cytokine IL-10 was elevated in PCLS from both groups upon" exact="viral infection" post="with 218 vs. 348 pg/mg in the non-sensitized group, and"/>
  <result pre="IL-10 was elevated in PCLS from both groups upon viral" exact="infection" post="with 218 vs. 348 pg/mg in the non-sensitized group, and"/>
  <result pre="1246 pg/mg) in tissue of HDM-sensitized mice. IL-33 remained unchanged upon" exact="viral infection" post="in both groups when compared to the corresponding UV-inactivated"/>
  <result pre="in tissue of HDM-sensitized mice. IL-33 remained unchanged upon viral" exact="infection" post="in both groups when compared to the corresponding UV-inactivated"/>
  <result pre="to the Mann–Whitney U test. n.s. = not significant During" exact="viral infection," post="IL-17A was also enhanced in PCLS isolated from non-sensitized"/>
  <result pre="of non-sensitized animals, although there was a trend. UV-inactivated RV" exact="infection" post="did not trigger IL-17 cytokine secretion compared to uninfected"/>
  <result pre="as rupintrivir may have an immune-modulatory effect in experimentally induced" exact="allergic asthma" post="with subsequent RV infection. We infected lung slices of"/>
  <result pre="rupintrivir may have an immune-modulatory effect in experimentally induced allergic" exact="asthma" post="with subsequent RV infection. We infected lung slices of"/>
  <result pre="imply that tissue slices of allergic mice showed a reduced" exact="epithelial" post="and antiviral response to RV infection ex vivo. At"/>
  <result pre="mice showed a reduced epithelial and antiviral response to RV" exact="infection" post="ex vivo. At the same time TH-2 cytokines such"/>
  <result pre="slices of untreated asthmatic animals. While the response to RV" exact="infection" post="of lung slices of asthmatic mice was expected, the"/>
  <result pre="of our study are mainly due to the ex vivo" exact="infection" post="of lung slices. Precision-cut lung slices enable evaluation of"/>
  <result pre="contain most cell types of lung tissue, including e.g. airway" exact="epithelial" post="cells and macrophages [16]. Lung slices of diseased donors"/>
  <result pre="on TCID50 or PCR. An explanation could be that the" exact="total" post="number of airway epithelial cells is very low in"/>
  <result pre="An explanation could be that the total number of airway" exact="epithelial" post="cells is very low in PCLS. The number of"/>
  <result pre="in PCLS. The number of virus produced by these few" exact="epithelial" post="cells was presumably too low to further increase the"/>
  <result pre="used interferon-gamma-induced protein 10 (IP-10) as a marker for successful" exact="infection" post="[20]. Actively replicating virus induces IP-10 in lung slices"/>
  <result pre="is unable to increase IP-10. Our results show that RV" exact="infection" post="ex vivo differs between lung slices obtained from asthmatic"/>
  <result pre="In contrast, PCLS of asthmatic mice showed reduced levels of" exact="epithelial" post="cytokines type I (IFN-α/β) and NK-cell secreted type II"/>
  <result pre="PCLS of asthmatic mice showed reduced levels of epithelial cytokines" exact="type I" post="(IFN-α/β) and NK-cell secreted type II (IFN-γ) IFN response"/>
  <result pre="levels of epithelial cytokines type I (IFN-α/β) and NK-cell secreted" exact="type II" post="(IFN-γ) IFN response to RV infection. These cytokines act"/>
  <result pre="cytokine IL-4. This is in line with results received from" exact="peripheral" post="blood mononuclear cells of healthy and asthmatic subjects, where"/>
  <result pre="blood mononuclear cells of healthy and asthmatic subjects, where RV" exact="infection" post="also increased IL-4 expression in asthmatic subjects [22]. IL-33"/>
  <result pre="TH-17 cells and is involved in mucosal as well as" exact="epithelial" post="host defense [26, 27]. Graser and colleagues showed that"/>
  <result pre="colleagues showed that IL-17A was responsible for RV clearance in" exact="epithelial" post="cells. IL-17A levels were diminished in asthmatic children infected"/>
  <result pre="with RV [28]. In accordance with our study, ex vivo" exact="infection" post="reduced IL-17A levels in lung slices of asthmatic animals."/>
  <result pre="tissue of asthmatic mice is capable of reacting to the" exact="viral infection" post="but with a reduced capacity of inducing protective immune"/>
  <result pre="of asthmatic mice is capable of reacting to the viral" exact="infection" post="but with a reduced capacity of inducing protective immune"/>
  <result pre="responses. These results confirm an impaired antiviral response towards RV" exact="infection" post="under allergic conditions in vivo [12]. Asthmatic patients experimentally"/>
  <result pre="patients experimentally infected with rhinovirus showed more severe disease, increased" exact="viral" post="burden and stronger airway inflammation in comparison to infected"/>
  <result pre="in comparison to infected healthy individuals [29, 30]. Patients with" exact="asthma" post="have an unmet need for effective treatment of virus-induced"/>
  <result pre="whether antiviral drugs such as rupintrivir exert beneficial effects in" exact="asthma" post="patients during exacerbation. Previous studies showed a strong antiviral"/>
  <result pre="Nevertheless, it failed to improve symptoms in patients with naturally" exact="acquired" post="colds [32]. The efficacy of rupintrivir in asthmatic patients"/>
  <result pre="this study, Rupintrivir showed only a minor effect on RV" exact="infection" post="in lung slices of healthy animals whereas it inhibited"/>
  <result pre="(Treg) cells into TH-17 like cells, therefore potentially contributing to" exact="asthma" post="severity [36]. Thus, reduced levels of IL-4 and IL-6"/>
  <result pre="different efficacy of antiviral drugs, which may depend on the" exact="disease" post="background of the infected individuals. Asthmatic patients may benefit"/>
  <result pre="Confocal image analysis and quantification after RV or UV-inactivated RV" exact="infection" post="of mouse PCLS. (a)-(d) Tissue slices were stained with"/>
  <result pre="phosphate buffered salt solution HDM House-dust mite IL Interleukin IU" exact="Infectious" post="units PCLS Precision-cut lung slices RV Rhinovirus TCID50 Tissue"/>
  <result pre="units PCLS Precision-cut lung slices RV Rhinovirus TCID50 Tissue culture" exact="infective" post="dose 50 UV Ultraviolet Publisher’s Note Springer Nature remains"/>
  <result pre="supported by Biomedical Research in the Endstage and Obstructive Lung" exact="Disease" post="Hannover (BREATH), Member of the German Centre for Lung"/>
  <result pre="financial and non-financial interests. References References 1.ContoliMMessageSDLaza-StancaVEdwardsMRWarkPABartlettNWKebadzeTMalliaPStanciuLAParkerHLet al.Role of deficient" exact="type III" post="interferon-lambda production in asthma exacerbationsNat Med2006121023102610.1038/nm146216906156 2.WarkPAJohnstonSLBucchieriFPowellRPuddicombeSLaza-StancaVHolgateSTDaviesDEAsthmatic bronchial epithelial"/>
  <result pre="References 1.ContoliMMessageSDLaza-StancaVEdwardsMRWarkPABartlettNWKebadzeTMalliaPStanciuLAParkerHLet al.Role of deficient type III interferon-lambda production in" exact="asthma" post="exacerbationsNat Med2006121023102610.1038/nm146216906156 2.WarkPAJohnstonSLBucchieriFPowellRPuddicombeSLaza-StancaVHolgateSTDaviesDEAsthmatic bronchial epithelial cells have a deficient"/>
  <result pre="type III interferon-lambda production in asthma exacerbationsNat Med2006121023102610.1038/nm146216906156 2.WarkPAJohnstonSLBucchieriFPowellRPuddicombeSLaza-StancaVHolgateSTDaviesDEAsthmatic bronchial" exact="epithelial" post="cells have a deficient innate immune response to infection"/>
  <result pre="bronchial epithelial cells have a deficient innate immune response to" exact="infection" post="with rhinovirusJ Exp Med200520193794710.1084/jem.2004190115781584 3.GavalaMLBashirHGernJEVirus/allergen interactions in asthmaCurr Allergy"/>
  <result pre="infection with rhinovirusJ Exp Med200520193794710.1084/jem.2004190115781584 3.GavalaMLBashirHGernJEVirus/allergen interactions in asthmaCurr Allergy" exact="Asthma" post="Rep20131329830710.1007/s11882-013-0344-123475539 4.EdwardsMRRegameyNVareilleMKieningerEGuptaAShoemarkASaglaniSSykesAMacintyreJDaviesJet al.Impaired innate interferon induction in severe therapy"/>
  <result pre="atopic asthmatic childrenMucosal Immunol2013679780610.1038/mi.2012.11823212197 5.JohnstonSLPattemorePKSandersonGSmithSLampeFJosephsLSymingtonPO'TooleSMyintSHTyrrellDAet al.Community study of role of" exact="viral" post="infections in exacerbations of asthma in 9-11 year old"/>
  <result pre="asthmatic childrenMucosal Immunol2013679780610.1038/mi.2012.11823212197 5.JohnstonSLPattemorePKSandersonGSmithSLampeFJosephsLSymingtonPO'TooleSMyintSHTyrrellDAet al.Community study of role of viral" exact="infections" post="in exacerbations of asthma in 9-11 year old childrenBMJ19953101225122910.1136/bmj.310.6989.12257767192"/>
  <result pre="al.Community study of role of viral infections in exacerbations of" exact="asthma" post="in 9-11 year old childrenBMJ19953101225122910.1136/bmj.310.6989.12257767192 6.NicholsonKGKentJIrelandDCRespiratory viruses and exacerbations"/>
  <result pre="in 9-11 year old childrenBMJ19953101225122910.1136/bmj.310.6989.12257767192 6.NicholsonKGKentJIrelandDCRespiratory viruses and exacerbations of" exact="asthma" post="in adultsBMJ199330798298610.1136/bmj.307.6910.9828241910 7.KhetsurianiNKazerouniNNErdmanDDLuXReddSCAndersonLJTeagueWGPrevalence of viral respiratory tract infections in"/>
  <result pre="6.NicholsonKGKentJIrelandDCRespiratory viruses and exacerbations of asthma in adultsBMJ199330798298610.1136/bmj.307.6910.9828241910 7.KhetsurianiNKazerouniNNErdmanDDLuXReddSCAndersonLJTeagueWGPrevalence of" exact="viral" post="respiratory tract infections in children with asthmaJ Allergy Clin"/>
  <result pre="viruses and exacerbations of asthma in adultsBMJ199330798298610.1136/bmj.307.6910.9828241910 7.KhetsurianiNKazerouniNNErdmanDDLuXReddSCAndersonLJTeagueWGPrevalence of viral" exact="respiratory" post="tract infections in children with asthmaJ Allergy Clin Immunol200711931432110.1016/j.jaci.2006.08.04117140648"/>
  <result pre="exacerbations of asthma in adultsBMJ199330798298610.1136/bmj.307.6910.9828241910 7.KhetsurianiNKazerouniNNErdmanDDLuXReddSCAndersonLJTeagueWGPrevalence of viral respiratory tract" exact="infections" post="in children with asthmaJ Allergy Clin Immunol200711931432110.1016/j.jaci.2006.08.04117140648 8.PatickAKBinfordSLBrothersMAJacksonRLFordCEDiemMDMaldonadoFDragovichPSZhouRPrinsTJet al.In"/>
  <result pre="UB: no exacerbation but impaired anti-viral mechanisms in a rhinovirus-chronic" exact="allergic asthma" post="mouse modelClin Sci (Lond)2014126556510.1042/CS2013017423822145 13.HenjakovicMSewaldKSwitallaSKaiserDMullerMVeresTZMartinCUhligSKrugNBraunAEx vivo testing of immune"/>
  <result pre="no exacerbation but impaired anti-viral mechanisms in a rhinovirus-chronic allergic" exact="asthma" post="mouse modelClin Sci (Lond)2014126556510.1042/CS2013017423822145 13.HenjakovicMSewaldKSwitallaSKaiserDMullerMVeresTZMartinCUhligSKrugNBraunAEx vivo testing of immune"/>
  <result pre="in precision-cut lung slicesToxicol Appl Pharmacol2008231687610.1016/j.taap.2008.04.00318504053 14.HeldHDMartinCUhligSCharacterization of airway and" exact="vascular" post="responses in murine lungsBr J Pharmacol19991261191119910.1038/sj.bjp.070239410205008 15.Neuhaus V, Danov"/>
  <result pre="16.AkramKMYatesLLMongeyRRotherySGaboriauDCASandersonJHindMGriffithsMDeanCHLive imaging of alveologenesis in precision-cut lung slices reveals dynamic" exact="epithelial" post="cell behaviourNat Commun201910117810.1038/s41467-019-09067-330862802 17.LehmannMBuhlLAlsafadiHNKleeSHermannSMutzeKOtaCLindnerMBehrJHilgendorffAet al.Differential effects of Nintedanib and"/>
  <result pre="17.LehmannMBuhlLAlsafadiHNKleeSHermannSMutzeKOtaCLindnerMBehrJHilgendorffAet al.Differential effects of Nintedanib and Pirfenidone on lung alveolar" exact="epithelial" post="cell function in ex vivo murine and human lung"/>
  <result pre="in ex vivo murine and human lung tissue cultures of" exact="pulmonary" post="fibrosisRespir Res20181917510.1186/s12931-018-0876-y30219058 18.SwitallaSLauensteinLPrenzlerFKnotheSForsterCFieguthHGPfennigOSchaumannFMartinCGuzmanCAet al.Natural innate cytokine response to immunomodulators"/>
  <result pre="adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and" exact="systemic" post="immune responses after administration into the lungVaccine2014323216322210.1016/j.vaccine.2014.04.01124731807 20.Reamon-Buettner S,"/>
  <result pre="pathway by Bronchobini® resulting in balanced immune response to rhinovirus" exact="infection" post="in mouse lung tissue slices. Int J Mol Sci."/>
  <result pre="slices. Int J Mol Sci. 2019;20. 21.McNabFMayer-BarberKSherAWackAO'GarraAType I interferons in" exact="infectious" post="diseaseNat Rev Immunol2015158710310.1038/nri378725614319 22.PapadopoulosNGStanciuLAPapiAHolgateSTJohnstonSLA defective type 1 response to"/>
  <result pre="21.McNabFMayer-BarberKSherAWackAO'GarraAType I interferons in infectious diseaseNat Rev Immunol2015158710310.1038/nri378725614319 22.PapadopoulosNGStanciuLAPapiAHolgateSTJohnstonSLA defective" exact="type 1" post="response to rhinovirus in atopic asthmaThorax20025732833210.1136/thorax.57.4.32811923551 23.Kurowska-StolarskaMStolarskiBKewinPMurphyGCorriganCJYingSPitmanNMirchandaniARanaBvan RooijenNet al.IL-33"/>
  <result pre="Med200917977278110.1164/rccm.200805-666OC19179489 25.KondoYYoshimotoTYasudaKFutatsugi-YumikuraSMorimotoMHayashiNHoshinoTFujimotoJNakanishiKAdministration of IL-33 induces airway hyperresponsiveness and goblet cell" exact="hyperplasia" post="in the lungs in the absence of adaptive immune"/>
  <result pre="hyperresponsiveness and goblet cell hyperplasia in the lungs in the" exact="absence of" post="adaptive immune systemInt Immunol20082079180010.1093/intimm/dxn03718448455 26.HirotaKAhlforsHDuarteJHStockingerBRegulation and function of innate"/>
  <result pre="roles of atopy and asthmaJ Allergy Clin Immunol20121301307131410.1016/j.jaci.2012.08.00522981791 30.MessageSDLaza-StancaVMalliaPParkerHLZhuJKebadzeTContoliMSandersonGKonOMPapiAet al.Rhinovirus-induced" exact="lower" post="respiratory illness is increased in asthma and related to"/>
  <result pre="of atopy and asthmaJ Allergy Clin Immunol20121301307131410.1016/j.jaci.2012.08.00522981791 30.MessageSDLaza-StancaVMalliaPParkerHLZhuJKebadzeTContoliMSandersonGKonOMPapiAet al.Rhinovirus-induced lower" exact="respiratory" post="illness is increased in asthma and related to virus"/>
  <result pre="Clin Immunol20121301307131410.1016/j.jaci.2012.08.00522981791 30.MessageSDLaza-StancaVMalliaPParkerHLZhuJKebadzeTContoliMSandersonGKonOMPapiAet al.Rhinovirus-induced lower respiratory illness is increased in" exact="asthma" post="and related to virus load and Th1/2 cytokine and"/>
 </snippets>
</snippetsTree>
